Tablets, Lozenges, Or Pills Patents (Class 424/464)
  • Patent number: 9018192
    Abstract: In accordance with this invention a novel pharmaceutical product containing efavirenz, emtricitabine and tenofovir DF are provided as a multicomponent unitary oral dosage form, component 1 comprising tenofovir DF (and, optionally, emtricitabine) and component 2 comprising efavirenz, wherein components 1 and 2 are in a stabilizing configuration. In preferred embodiments component 1 is made by dry granulation.
    Type: Grant
    Filed: October 10, 2013
    Date of Patent: April 28, 2015
    Assignee: Bristol-Myers Squibb & Gilead Sciences, Inc.
    Inventors: Terrence C. Dahl, Munir A. Hussain, Robert A. Lipper, Robert L. Jerzewski, Mark M. Menning, Reza Oliyai, Taiyin Yang
  • Patent number: 9017722
    Abstract: A tablet characterized by comprising 5-methyl-1-phenyl-2-(1H)-pyridone as the main ingredient and, based on the main ingredient, 10 to 50 wt. % excipient, 5 to 40 wt. % disintegrator, 1 to 10 wt. % binder, 0.5 to 5 wt. % lubricant, 2 to 6 wt. % coating basis, and 0.05 to 3 wt. % light-shielding agent, wherein the odor or bitterness of the 5-methyl-1-phenyl-2-(1H)-pyridone is masked and the light stability is improved.
    Type: Grant
    Filed: October 26, 2012
    Date of Patent: April 28, 2015
    Assignee: Intermune, Inc.
    Inventors: Gakuji Kiyonaka, Yoshihiro Furuya, Yusuke Suzuki
  • Patent number: 9011907
    Abstract: The present invention relates to a pharmaceutical or nutraceutical preparation comprising a) a core containing a pharmaceutically or nutraceutically active substance and a substance that acts in a modulatory manner with regard of the release of pharmaceutically or nutraceutically active substances; and b) a controlling layer surrounding the core comprising i) 55 to 92% by weight based on the total weight of (meth)acrylic copolymers present in the layer of one or a mixture of a plurality of (meth)acrylate copolymers composed of 80 to 98% by weight based on the weight of the (meth)acrylic copolymer of structural units derived from C1 to C4 alkyl esters of (meth)acrylic acid and 2 to 20% by weight based on the weight of the (meth)acrylic copolymer of structural units derived from (meth)acrylate monomers with a quaternary ammonium group in the alkyl radical; and ii) 8 to 45% by weight based on the total weight of (meth)acrylic copolymers present in the layer of one or a mixture of a plurality of (meth)acrylate co
    Type: Grant
    Filed: February 1, 2008
    Date of Patent: April 21, 2015
    Assignee: Evonik Röhm GmbH
    Inventors: Hema Ravishankar, Shradda Bodinge, Hans-Ulrich Petereit
  • Patent number: 9011910
    Abstract: A method of treating the symptoms of spasticity comprises implanting a reservoir-based drug delivery composition into a subject to systemically deliver a therapeutically effective amount of tizanidine to the subject for a long period of time (e.g., one month or one year). The drug delivery composition may include a rate-controlling excipient (e.g., an elastomeric polymer) defining a reservoir containing at least one discrete solid dosage form (e.g., one or more pellets), which includes tizanidine free base and optionally, a sorption enhancer.
    Type: Grant
    Filed: May 22, 2013
    Date of Patent: April 21, 2015
    Assignee: Braeburn Pharmaceuticals BVBA SPRL
    Inventor: Alexander Schwarz
  • Patent number: 9011911
    Abstract: The present invention pertains to a high drug load tablet comprising an active ingredient Compound I of formula or a pharmaceutically acceptable salt thereof in an amount from about 30% to 80% in weight of the active moiety based on the total weight of the tablet.
    Type: Grant
    Filed: January 23, 2014
    Date of Patent: April 21, 2015
    Assignee: Novartis AG
    Inventors: Christian-Peter Luftensteiner, Jean-Claude Bianchi, Joerg Ogorka, Oskar Kalb
  • Publication number: 20150104508
    Abstract: Systems, methods, compositions, and devices related to the delivery of one or more biologically active agents to a body include the admixture of one or more biologically active agents with one or more biocompatible polymeric mixtures in a solid-state shear extrusion system. The extrusion systems may include one or more extrusion screws. One or more portions of the one or more extrusion screws, one or more extrusion system active elements, one or more barrel sections, and/or one or more extruder work zones may be temperature controlled to maintain a temperature of the biocompatible polymeric mixture in contact therewith at or below the liquefication temperature of the biocompatible polymeric materials. The resulting compositions from the extrusion systems may be fabricated into devices to deliver the one or more biologically active agents to a body.
    Type: Application
    Filed: October 10, 2014
    Publication date: April 16, 2015
    Inventors: Philip BRUNNER, Mark TAPSAK
  • Publication number: 20150104509
    Abstract: A troche comprising at least 5 mg hyaluronan, wherein the troche is adherent, and wherein hyaluronan is released from the troche, is used to treat mucositis, including stomatitis, vestibulitis, aphthous ulcerations, lichen planus and Behcet's syndrome. A method for treating or preventing mucositis in a patient is provided, comprising applying to a mucosal surface or a tooth or orthodontic brace of a patient in need thereof an adhering troche comprising at least 5 mg hyaluronan.
    Type: Application
    Filed: October 15, 2014
    Publication date: April 16, 2015
    Inventor: Jeffrey Haley
  • Publication number: 20150104513
    Abstract: A coating film comprising ethyl cellulose as a component A and an (ethyl acrylate)-(methyl methacrylate) copolymer or a plasticized vinyl acetate polymer as a component B, and having a tensile elongation of 150% or more and a tensile strength of 9 N or more.
    Type: Application
    Filed: December 5, 2014
    Publication date: April 16, 2015
    Applicant: ASAHI KASEI CHEMICALS CORPORATION
    Inventors: Naoya YOSHIDA, Kazuhiro OBAE
  • Patent number: 9005658
    Abstract: A pharmaceutical pellet is provided, comprising a spherical core containing the active substance with a smooth surface and a coating on the core, which controls pH-independent release of the active substance. With a pellet of this kind, the release of the active substance may follow a profile with a lag-phase from 60 minutes to 840 minutes, where during the lag-phase a proportion of 5 wt. % or less of the active substance is released. Furthermore, the active substance may be released from the pellet with a profile such that, after the lag-phase, the release of the active substance is between 3 and 25 wt. % per hour. The active substance is a metoprolol salt.
    Type: Grant
    Filed: December 15, 2006
    Date of Patent: April 14, 2015
    Assignee: ADD Advanced Drug Delivery Technologies Ltd.
    Inventors: Burkhard Schlutermann, Manfred Kohlmeyer
  • Patent number: 9005659
    Abstract: Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.
    Type: Grant
    Filed: February 12, 2013
    Date of Patent: April 14, 2015
    Assignee: Purdue Pharma L.P.
    Inventors: Curtis Wright, Benjamin Oshlack, Christopher Breder
  • Publication number: 20150098996
    Abstract: A nicotine lozenge provided herein includes a body that is partially or wholly receivable in an oral cavity. The body includes a soluble-fiber matrix and nicotine or a derivative thereof dispersed in the soluble-fiber matrix. In some cases, a nicotine lozenge provided herein includes at least 40 weight percent of soluble fiber. In some cases, soluble fiber in a nicotine lozenge provided herein can include maltodextrin. The nicotine lozenge is adapted to release the nicotine or a derivative thereof from the body when the body is received within the oral cavity of an adult consumer and exposed to saliva. A method of making nicotine lozenges provided herein includes forming a molten mixture of at least 40 weight percent soluble fiber, nicotine, and less than 15 weight percent water while maintaining a mixture temperature of less than 150° C. and portioning the molten mixture into a plurality of nicotine lozenges. In some cases, the ingredients can be mixed to form the molten mixture in an extruder.
    Type: Application
    Filed: October 3, 2014
    Publication date: April 9, 2015
    Inventors: Feng Gao, Diane L. Gee, Phillip M. Hulan, Shuzhong Zhuang, William J. Burke
  • Patent number: 8999384
    Abstract: The present invention provides a method of creating a macro environment in the stomach for immediate release of acid labile compounds stable at alkaline or near alkaline pH comprising the step of administering a composition comprising acid labile compound stable at alkaline or near alkaline pH together with a water soluble buffer, a water insoluble buffer, a disintegrant and pharmaceutically acceptable excipients. The present invention also provides a pharmaceutical composition of a multi component system in which one component essentially contains an acid labile drug and the other component comprises a fast releasing buffer composition along with pharmaceutically acceptable excipients for oral administration and ingestion by a subject, and process for preparing the same.
    Type: Grant
    Filed: January 10, 2011
    Date of Patent: April 7, 2015
    Inventors: Muneera Mohamed Shafee, Ruckmani Kandasamy, Thusleem Omar Abdulgani, Saleem Zainuddin Shaikh, Anand Vasantharao Kondaguli
  • Patent number: 8999388
    Abstract: Drug tablets that include a prolonged-release core and an immediate-release layer or shell are prepared with a thin barrier layer of drug-free polymer between the prolonged-release and immediate-release portions of the tablet. The barrier layer is penetrable by gastrointestinal fluid, thereby providing full access of the gastrointestinal fluid to the prolonged-release core, but remains intact during the application of the immediate-release layer, substantially reducing or eliminating any penetration of the immediate-release drug into the prolonged-release portion.
    Type: Grant
    Filed: March 6, 2014
    Date of Patent: April 7, 2015
    Assignee: Depomed, Inc.
    Inventors: Jong Lim, John N. Shell, Jenny Louie-Helm
  • Patent number: 8999386
    Abstract: An oral methylphenidate extended release tablet is described, which can be scored and still retain its extended release profile. The tablet contains a combination of an uncoated methylphenidate-ion exchange resin complex, a barrier coated methylphenidate-ion exchange resin complex-matrix, and an uncomplexed methylphenidate active component. Following administration of a single dose of the extended release methylphenidate chewable tablet, a therapeutically effective amount of methylphenidate is reached in less than about 20 minutes and the composition provides a twelve-hour extended release profile.
    Type: Grant
    Filed: June 10, 2014
    Date of Patent: April 7, 2015
    Assignee: TRIS Pharma, Inc.
    Inventors: Yu-Hsing Tu, Ashok Perumal, Kalyan Kathala
  • Patent number: 8999385
    Abstract: The invention relates to a method for producing an oral form of administration which decomposes immediately and releases active ingredients in the mouth. According to said method, (a) an anionic pharmaceutical active ingredient is intensively mixed with (b) a copolymer consisting of radically polymerized C1-C4 esters of the acrylic acid or methacrylic acid and other (meth)acrylate monomers containing functional tertiary amino groups, and (c) between 5 and 50 wt. %, in relation to (b), of a C12-C22 carboxylic acid in the melted mass; the mixture is solidified and ground to form a powder containing active ingredients having an average particle size of 200 ?m or less; and the powder is encapsulated in a water-soluble matrix consisting of pharmaceutically standard adjuvants, on the condition that no more than 3 wt. %, in relation to the copolymer, of emulsifiers with an HLB value of at least 14 must be contained therein.
    Type: Grant
    Filed: November 15, 2012
    Date of Patent: April 7, 2015
    Assignee: EVONIK RÖHM GmbH
    Inventors: Hans-Ulrich Petereit, Christian Meier, Andreas Gryczke
  • Patent number: 8992974
    Abstract: Disclosed are preparations and formulations of high thermodynamic activity lipophilic associations (LA), in which there is pairing between an ionizable pharmaceutical agent and a lipophilic species having ionic characteristics opposite to that of the pharmaceutical agent. Such lipophilic associations manifest high thermodynamic activity, as evidenced by their being predominantly in a liquid phase at room temperature or solvated in a lower-than-water dielectric solvent. Further the pharmaceutical agent being solubilized means that dissolution is not rate limiting to transmucosal absorption. This LA or LA-solvate is formulated into a low dielectric dosage form, from when, upon the dosage form's hydration, the pharmaceutical agent is driven through the mucosal tissue and into systemic circulation. The invention therefore provides an enhanced transmucosal drug delivery system for ionizable pharmaceutical agents at or near physiological pH.
    Type: Grant
    Filed: February 24, 2004
    Date of Patent: March 31, 2015
    Assignee: Pharmaceuticals Productions, Inc.
    Inventor: John A. McCarty
  • Publication number: 20150079166
    Abstract: The present disclosure provides solid compositions comprising a stabilized salt of aminocarboxylic acid. Pharmaceutical compositions comprising [(1R,5S,6S)-6-(aminomethyl)-3-ethylbicyclo[3.2.0]hept-3-en-6-yl]acetic acid monobenzenesulfonate in combination with appropriate additives are also provided.
    Type: Application
    Filed: November 25, 2014
    Publication date: March 19, 2015
    Inventors: Shinichiro Tajiri, Masami Takemura, Shinji Yoshinaga
  • Patent number: 8980322
    Abstract: The present invention provides a controlled release composition showing release of an active ingredient (proton pump inhibitor) controlled in two or more steps at different release rates, which contains 1) a release-controlled part A capable of controlling release of the active ingredient to occur at a predetermined rate, 2) a release-controlled part B capable of controlling release of the active ingredient to occur at a predetermined rate lower than the release rate of the release-controlled part A, and where necessary, 3) a release-controlled part C capable of controlling release of the active ingredient to occur at a predetermined rate faster than the release rate of the release-controlled part B, wherein the release of the active ingredient from the release-controlled part B precedes the release of the active ingredient from the release-controlled part A (when release-controlled part C is contained, the release of the active ingredient from the release-controlled part C precedes the release of the active
    Type: Grant
    Filed: March 16, 2004
    Date of Patent: March 17, 2015
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Naoki Nagahara, Keiko Miyamoto, Yohko Akiyama
  • Patent number: 8980321
    Abstract: A drug in a solubility-improved form is combined with a concentration-enhancing polymer in a sufficient amount so that the combination provides substantially enhanced drug concentration in a use environment relative to a control comprising the same amount of the same solubility-improved form of drug without the concentration-enhancing polymer.
    Type: Grant
    Filed: July 14, 2014
    Date of Patent: March 17, 2015
    Assignee: Bend Research, Inc.
    Inventors: William J. Curatolo, Ravi M. Shanker, Walter C. Babcock, Dwayne T. Friesen, James A. S. Nightingale, Douglas A. Lorenz
  • Patent number: 8980305
    Abstract: There is provided pharmaceutical compositions for the treatment of pain comprising a pharmacologically-effective amount of an opioid analgesic, or a pharmaceutically-acceptable salt thereof, presented in particulate form upon the surfaces of carrier particles comprising a pharmacologically-effective amount of an opioid antagonist, or a pharmaceutically-acceptable salt thereof, which carrier particles are larger in size than the particles of the opioid analgesic. The compositions are also useful in prevention of opioid abuse by addicts.
    Type: Grant
    Filed: March 13, 2013
    Date of Patent: March 17, 2015
    Assignee: Orexo AB
    Inventor: Anders Pettersson
  • Patent number: 8980870
    Abstract: A pharmaceutical composition comprising 3 wt. % to 50 wt. % telmisartan dispersed in a dissolving matrix comprising: (a) a basic agent in a molar ratio of basic agent:telmisartan of 1:1 to 10:|1|; (b) about 1 wt. % to about 20 wt. % of a surfactant or emulsifier; (c) 25 wt. % to 70 wt. % of a water-soluble |diluent|; and (d) 0 wt. % to 20 wt. % of one or more additional excipients and/or |adjuvants|; wherein the sum of all components is 100%, methods of making such pharmaceutical compositions, and their use.
    Type: Grant
    Filed: September 18, 2003
    Date of Patent: March 17, 2015
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Manabu Nakatani, Sawada Takeshi, Toshimitsu Ohki, Kenzo Toyoshima
  • Publication number: 20150072000
    Abstract: Method for producing enteric microcapsules without coating, containing diclofenac or one of the salts thereof with satisfactory anti-inflammatory activity and low gastric aggressiveness; and a pharmaceutical composition containing them. The method comprises a) preparing a mixture in water-ethanol with an alginate salt, adding diclofenac or one of the salts thereof previously diluted with a surfactant and sodium bicarbonate; b) adding the previous solution to a solution with a calcium salt; c) resuspending the microcapsules obtained and isolated in an aqueous solution of the alginate salt; and d) isolating, drying and sieving through 1000 and 250 micron meshes the microcapsules obtained; and selecting the fraction comprised between both meshes. The pharmaceutical composition can be an oral composition, tablets, chewable tablets, or a powder for suspension in water.
    Type: Application
    Filed: March 20, 2012
    Publication date: March 12, 2015
    Applicants: Eastbrand Holdings GMBH, Laboratorios Bago S.A.
    Inventor: Mario Atilio Los
  • Patent number: 8974825
    Abstract: A novel pharmaceutical composition, which comprises a therapeutically effective amount of active principle(s) or a pharmaceutically acceptable salt or enantiomer or polymorph thereof, optionally one or more release controlling agent(s) and pharmaceutical acceptable excipient(s) thereof, wherein the composition is formulated to increase the residence time of the said pharmaceutical composition and/or active principle(s) in the gastrointestinal tract. A novel pharmaceutical composition comprising at least two entities wherein one entity is an immediate release/fast release and the other is controlled release. A pharmaceutical composition comprising at least two entities wherein one entity is an immediate release/fast release and the other is bioadhesive. A pharmaceutical composition comprising: at least two entities wherein one entity is controlled release and the other is bioadhesive All the three compositions are formulated to increase the residence time of active principle(s) in the gastrointestinal tract.
    Type: Grant
    Filed: June 24, 2008
    Date of Patent: March 10, 2015
    Assignee: Lupin Limited
    Inventors: Harshal Anil Jahagirdar, Rajesh Kulkarni, Shirishkumar Kulkarni
  • Patent number: 8974824
    Abstract: The present invention discloses stable, solid oral pharmaceutical composition comprising Lanthanum carbonate having more than 6 molecules of water per molecule of lanthanum carbonate and pharmaceutically acceptable carriers or diluents, wherein said carrier or diluent excludes monosaccharide/s or disaccharide/s, such that the composition has comparable in-vitro dissolution profile similar to that of FOSRENOL®. Also disclosed is a wet granulation process for making the same.
    Type: Grant
    Filed: March 24, 2009
    Date of Patent: March 10, 2015
    Assignee: Mylan Laboratories Ltd.
    Inventors: Nagaraj Amminabavi, Indu Bhushan, Satish Kumar Jain, Subhash Gore, Gnanadeva Chalapathy Gudipati, Balakrishnan Chinnu, Subramanian Iyer, Manoj P Kumar, Rajesh S Gupta
  • Patent number: 8974823
    Abstract: Solid compositions of low-solubility drugs and poloxamers that provide concentration enhancement when administered to an aqueous environment of use are disclosed.
    Type: Grant
    Filed: December 20, 2004
    Date of Patent: March 10, 2015
    Assignee: Bend Research, Inc.
    Inventors: Daniel Tod Smithey, Dwayne Thomas Friesen, Warren Kenyon Miller, Walter Christian Babcock
  • Patent number: 8968776
    Abstract: The invention provides new benzimidazole compositions, comprising: (a) a core containing said benzimidazole active ingredient; (b) an intermediate layer; and (c) an enteric layer; said core being substantially free of binder. The invention also provides a process for manufacturing the composition of the invention.
    Type: Grant
    Filed: May 16, 2013
    Date of Patent: March 3, 2015
    Assignee: UCB, Inc.
    Inventors: Pawan Seth, Benoît Schmitt
  • Patent number: 8969369
    Abstract: Abuse-resistant, controlled release opioid tablets are a combination containing an opioid antagonist such as naloxone at a level above that needed to suppress the euphoric effect of the opioid, if the combination were crushed to break the controlled release properties causing the opioid and opioid antagonist to be released as a immediate release product as a single dose. The controlled release nature of the table prevents the accumulation of orally effective amounts of opioid antagonist when taken normally. The opioid antagonist is contained in a controlled-release matrix and released, over time, with the opioid.
    Type: Grant
    Filed: December 20, 2013
    Date of Patent: March 3, 2015
    Assignee: Purdue Pharma L.P.
    Inventors: Frank S. Caruso, Huai-Hung Kao
  • Patent number: 8969371
    Abstract: The present disclosure relates to compositions, kits, uses, systems and methods related to naltrexone plus bupropion for treating an overweight or obese subject at increased risk of adverse cardiovascular outcomes. Preferably, the subject has had type-two diabetes for a period of less than 6 years or is a current smoker, optionally that does not have type-two diabetes.
    Type: Grant
    Filed: July 2, 2014
    Date of Patent: March 3, 2015
    Assignee: Orexigen Therapeutics, Inc.
    Inventors: Preston Klassen, Kristin Taylor
  • Patent number: 8962018
    Abstract: The invention relates to a solid formulation for the oral administration of olanzapine that comprises a core of anhydrous olanzapine Form I or a pharmaceutically acceptable salt thereof and, optionally, pharmaceutically acceptable excipients, said core being coated with a functional polymer that acts as filmogenic agent. The method for obtaining it comprises: i) providing anhydrous olanzapine Form I or a salt thereof and, optionally, pharmaceutically acceptable excipients in solid form; ii) providing a functional polymer that acts as filmogenic agent; iii) preparing a dispersion of said functional polymer in an aqueous medium,—and applying the dispersion obtained in step iii) onto the solid form of step i).
    Type: Grant
    Filed: December 19, 2006
    Date of Patent: February 24, 2015
    Assignee: Laboratorios Lesvi, S.L.
    Inventors: Ignacio Diez Martin, Carmen Ubeda Perez, Pablo Pablo Alba
  • Patent number: 8961498
    Abstract: Electronic pill (1, 11, 21) comprising a plurality of medicine reservoirs (2, 12, 22), each of the reservoirs comprising a discharge opening (3, 13, 23) covered by a removable cover (6, 16, 26). The pill comprises at least one actuator responsive to control circuitry for removing the cover from the discharge opening (3, 13, 23). The actuator can for example be a spring loaded piston (4) breaking a foil cover when dispensing the medicament. 5 Alternatively, the cover can be a rotatable disk (16) or cylinder (26) with an opening (17, 27) which can be brought in line with the discharge opening of a reservoir under the action of the actuator.
    Type: Grant
    Filed: June 18, 2009
    Date of Patent: February 24, 2015
    Assignee: Medimetrics Personalized Drug Delivery
    Inventors: Hans Zou, Jeff Shimizu, Lucian R. Albu, Johan F. Dijksman
  • Patent number: 8962017
    Abstract: A high-efficacy, long-acting formulation of silymarin, comprising silymarin solid dispersion, silymarin-loaded silica nanoparticles, slow-release matrix material and release enhancer, wherein the mass ratio of these components is silymarin solid dispersion:silymarin-loaded silica nanoparticles:slow-release matrix material:release enhancer=1:0.5˜1.25:0.1˜0.3:0.1˜0.3; the drug loading rate of the said silymarin-loaded silica nanoparticles is 51.95%-52.87%; the said silymarin solid dispersion contains povidone K30, soybean lecithin and acrylic resin IV, and the mass ratio between silymarin and other medical accessories in silymarin solid dispersion is silymarin:povidone K30:soybean lecithin:acrylic resin IV=1:1˜3:0.3˜0.8:0.2˜0.5. Compared with the existing formulations, the half life of the high-efficacy, long-acting formulation of silymarin disclosed in this invention is 2.3 times longer while the mean residence time (MRT) of which is 9.
    Type: Grant
    Filed: November 23, 2009
    Date of Patent: February 24, 2015
    Assignee: Jiangsu University
    Inventors: Ximing Xu, Jiangnan Yu, Shanshan Tong, Yuan Zhu, Xia Cao
  • Patent number: 8962022
    Abstract: The present invention is directed to compositions of taste-masked microparticles comprising a substituted benzhydrylpiperazine coated and a taste-masking layer comprising a water-insoluble polymer and a gastrosoluble polymer, and methods of making such taste-masked microparticles. The present invention is also directed to stable orally disintegrating compositions comprising taste-masked microparticles of a substituted benzhydrylpiperazine and rapidly dispersing granules, and methods of making such orally disintegrating compositions.
    Type: Grant
    Filed: March 27, 2008
    Date of Patent: February 24, 2015
    Assignee: Aptalis Pharmatech, Inc.
    Inventor: Gopi Venkatesh
  • Patent number: 8962019
    Abstract: The invention relates to a sustained release formulation for delivering one or more pharmaceutically active agents. The formulation comprises cross-linked high amylose starch and at least one pharmaceutically active agent, and optionally can be subdivided into smaller dosage forms where the smaller dosage forms have substantially the same sustained release properties as the formulation from which they were derived. The formulations can provide sustained release for up to at least 24 hours, and because of their divisability permits a recipient of the active agent or the person administering the active agent to titrate the dosage of the agent.
    Type: Grant
    Filed: October 15, 2010
    Date of Patent: February 24, 2015
    Assignee: Angelini Pharma, Inc.
    Inventors: Sonia Gervais, Damon Smith, Pauline Contamin, Rachid Ouzerourou, My Linh Ma
  • Publication number: 20150050335
    Abstract: The present disclosure relates to methods for making extended-release formulations of water-soluble active pharmaceutical ingredients such as metformin HCl. In one aspect, the disclosure provides a method that includes adding an aqueous solution of an active pharmaceutical ingredient to an agitated mixture of one or more release-modifying polymers and optionally one or more binders in one or more organic solvents, the one or more organic solvents together being an antisolvent for the active pharmaceutical ingredient, water being sufficiently soluble in the one or more organic solvents such that the water added as part of the aqueous solution dissolves in the mixture, the addition thereby precipitating the active pharmaceutical ingredient; separating the active pharmaceutical ingredient and the one or more release-modifying polymers and, if present, the one or more binders from the one or more organic solvents to yield co-processed particles; and drying the co-processed particles.
    Type: Application
    Filed: February 28, 2013
    Publication date: February 19, 2015
    Inventors: Deniz Erdemir, Shih-Ying Chang, Divyakant Desai, San Kiang
  • Publication number: 20150050333
    Abstract: Provided is a pharmaceutical composition having a single dosage form including a compartment including olmesartan medoxomil; and a compartment including rosuvastatin or its salt, wherein said compartments are formulated in a separate form. In the pharmaceutical composition of the present invention, olmesartan medoxomil and rosuvastatin or its salt are formulated into a combination dosage form having separate compartments, thereby being able to solve the absorption-inhibition problem originated from drug interaction. In addition, the use of a certain disintegrant(s) makes it possible to obtain a combination formulation bioequivalent to the single formulation of each of drugs.
    Type: Application
    Filed: March 22, 2013
    Publication date: February 19, 2015
    Applicant: DAEWOONG PHARMACEUTICAL CO., LTD.
    Inventors: Hee-Chul Chang, Bok-Ki Kang, Jun-Ku Kim
  • Patent number: 8956650
    Abstract: An intrabuccally rapidly disintegrating tablet which is manufactured by a simple method, has an enough practical hardness and is rapidly disintegrated in the buccal cavity and its production method. The intrabuccally rapidly disintegrating tablet is produced by growing a powder material into a granulated material with a fixed particle diameter, the powder material including a sugar alcohol or a saccharide as main ingredient, each of which is first particle having an average particle diameter of not more than 30 ?m, by mixing thus obtained granulated material with an active ingredient and a disintegrant, and by compressing the mixture into a predetermined shape.
    Type: Grant
    Filed: January 17, 2013
    Date of Patent: February 17, 2015
    Assignee: Kyowa Hakko Kirin Co., Ltd.
    Inventors: Motohiro Ohta, Eiji Hayakawa, Kunio Ito, Sanji Tokuno, Kiyoshi Morimoto, Yasushi Watanabe
  • Publication number: 20150037410
    Abstract: The present disclosure relates to a solid composition comprising ranolazine and a spray-dried phosphoric acid salt of dronedarone in a bilayer tablet.
    Type: Application
    Filed: July 29, 2014
    Publication date: February 5, 2015
    Applicant: Gilead Sciences, Inc.
    Inventors: Michael Gerber, Neal Huang, Joanna M. Koziara, Feng Zhang
  • Patent number: 8945618
    Abstract: An intrabuccally rapidly disintegrating tablet which is manufactured by a simple method, has an enough practical hardness and is rapidly disintegrated in the buccal cavity and its production method. The intrabuccally rapidly disintegrating tablet is produced by growing a powder material into a granulated material with a fixed particle diameter, the powder material including a sugar alcohol or a saccharide as main ingredient, each of which is first particle having an average particle diameter of not more than 30 ?m, by mixing thus obtained granulated material with an active ingredient and a disintegrant, and by compressing the mixture into a predetermined shape.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: February 3, 2015
    Assignee: Kyowa Hakko Kirin Co., Ltd.
    Inventors: Motohiro Ohta, Eiji Hayakawa, Kunio Ito, Sanji Tokuno, Kiyoshi Morimoto, Yasushi Watanabe
  • Patent number: 8946229
    Abstract: The present invention relates to pharmaceutical compositions for oral administration of active compounds.
    Type: Grant
    Filed: August 28, 2008
    Date of Patent: February 3, 2015
    Assignee: UCB, Inc.
    Inventors: Domenico Fanara, Monique Berwaer, Anthony Guichaux, Michel Deleers
  • Patent number: 8940329
    Abstract: Described are granules composed at least of a substantial amount of ibuprofen, at least one pharmaceutically-acceptable super disintegrant, and at least one pharmaceutically-acceptable binder different from the super disintegrant(s), the super disintegrant(s) being substantially uniformly dispersed throughout the granules. The methods for preparing such granules are described. The granules are useful in forming solid dosage forms such as filled capsules or compressed solid dosage forms.
    Type: Grant
    Filed: October 28, 2005
    Date of Patent: January 27, 2015
    Assignee: SI Group, Inc.
    Inventors: Patrick C. Hu, Gregory H. Lambeth, Arcelio J. Malcolm
  • Patent number: 8940330
    Abstract: There is provided pharmaceutical compositions for the treatment of e.g. opioid dependency comprising microparticles of a pharmacologically-effective amount of buprenorphine, or a pharmaceutically-acceptable salt thereof, in associative admixture with particles comprising a weak acid, or particles comprising weakly-acidic buffer forming materials. The composition may further comprise a disintegrant and/or particles of a pharmacologically-effective amount of naloxone, or a pharmaceutically-acceptable salt thereof. The compositions are useful in the treatment of opioid dependency/addiction and/or pain.
    Type: Grant
    Filed: September 18, 2012
    Date of Patent: January 27, 2015
    Assignee: Orexo AB
    Inventor: Andreas Fischer
  • Patent number: 8940344
    Abstract: Provided are oral products that provide engaging and flavorful experiences to a user. The oral product includes a plurality of capsules, a powdered component, a viscous component and a binder that create a matrix that is molded into a shape. In a preferred embodiment, the capsules provide functional and flavorful ingredients. In an embodiment, the matrix is enclosed in a porous material that forms a pouch.
    Type: Grant
    Filed: June 6, 2008
    Date of Patent: January 27, 2015
    Assignee: Philip Morris USA Inc.
    Inventors: Danielle R. Crawford, Shalva Gedevanishvili, William R. Sweeney, Chris Irving
  • Publication number: 20150024047
    Abstract: The present invention relates to pharmaceutical compositions containing a solid dispersion of N-[2,4-Bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide including formulations of the solid dispersions into powders, granules and mini-tablets, methods for manufacturing and processing the powders, granules and mini-tablets, and methods for treating cystic fibrosis employing the pharmaceutical composition.
    Type: Application
    Filed: October 9, 2014
    Publication date: January 22, 2015
    Inventors: Eleni Dokou, Shahla Jamzad, John P. Caesar, JR., Majed Fawaz, Laura Das, Chong-Hui Gu, Patricia Nell Hurter, Meghna Jai Israni, Meghan M. Johnston, Dragutin Knezic, Andrew G. Kuzmission, HongRen Wang
  • Patent number: 8936808
    Abstract: The invention is directed in part to oral dosage forms comprising a combination of an opioid agonist, acetaminophen and an orally active opioid antagonist, the opioid antagonist being included in a ratio to the opioid agonist to provide a combination product which is analgesically effective when the combination is administered orally, but which is aversive in a physically dependent subject. Preferably, the amount of opioid antagonist included in the combination product provides at least a mildly negative, “aversive” experience in physically dependent addicts (e.g., precipitated abstinence syndrome).
    Type: Grant
    Filed: September 18, 2014
    Date of Patent: January 20, 2015
    Assignee: Purdue Pharma L.P.
    Inventors: Robert F. Kaiko, Robert D. Colucci
  • Publication number: 20150017236
    Abstract: Provided herein are methods of stabilizing thyroid hormone, preventing a thyroid hormone from being oxidized, producing a formulation of thyroid hormone having a uniform potency, and reducing the exposure of a thyroid hormone to oxygen, light, moisture, or high temperature. Such methods comprise coating said thyroid hormone to provide a solid form comprising thyroid hormone coated with a coating material. Also provided are pharmaceutical compositions comprising a solid form of a thyroid hormone, wherein said solid form comprises thyroid hormone coated with a coating material. The invention also provides pharmaceutical compositions produced by the methods. Unit dosage forms and batches comprising such pharmaceutical compositions are also provided.
    Type: Application
    Filed: July 8, 2014
    Publication date: January 15, 2015
    Inventor: Jefferson J. GREGORY
  • Publication number: 20150017237
    Abstract: The present invention relates to an oral dosage form comprising crystalline lopinavir and crystalline ritonavir. The invention further relates to methods of preparing said oral dosage forms containing the above pharmaceutical active agents.
    Type: Application
    Filed: March 6, 2013
    Publication date: January 15, 2015
    Inventors: Dominique Meergans, Konstantin Holfinger
  • Patent number: 8932630
    Abstract: The invention is directed in part to oral dosage forms comprising a combination of an orally analgesically effective amount of an opioid agonist and an orally active opioid antagonist, the opioid antagonist being included in a ratio to the opioid agonist to provide a combination product which is analgesically effective when the combination is administered orally, but which is aversive in a physically dependent subject. Preferably, the amount of opioid antagonist included in the combination product provides at least a mildly negative, “aversive” experience in physically dependent addicts (e.g., precipitated abstinence syndrome).
    Type: Grant
    Filed: September 18, 2014
    Date of Patent: January 13, 2015
    Assignee: Purdue Pharma L.P
    Inventors: Robert F. Kaiko, Robert D. Colucci
  • Patent number: 8933057
    Abstract: Preparation, in-vitro and in vivo characterization of novel forms of (1-hydroxy-2-imidazol-1-yl-1-phosphono-ethyl) phosphonic acid, suitable for pharmaceutical compositions in drug delivery systems for humans.
    Type: Grant
    Filed: February 13, 2013
    Date of Patent: January 13, 2015
    Assignee: Thar Pharmaceuticals, Inc.
    Inventors: Mazen Hanna, Ning Shan, Miranda L. Cheney, David R. Weyna, Raymond K. Houck
  • Patent number: 8932629
    Abstract: A particulate co-processed composition comprising microcrystalline cellulose and at least one sugar alcohol is disclosed. A preferred sugar alcohol is mannitol. The composition has an improved compactability profile, lubricant sensitivity, and ejection profile compared to microcrystalline cellulose and the at least one sugar alcohol, either alone or in combination as a simple dry blend, in the preparation of solid dosage formulations, such as tablets. Tablets comprising the particulate co-processed composition, an active, and, optionally, one or more other excipients, and method for their preparation, are also disclosed.
    Type: Grant
    Filed: October 26, 2007
    Date of Patent: January 13, 2015
    Assignee: FMC Corporation
    Inventors: Jian-Xin Li, Brian Carlin, Thomas Ruszkay
  • Publication number: 20150010627
    Abstract: The present invention relates to new pharmaceutical compositions of flurbiprofen or a pharmaceutically acceptable salt thereof and glucosamine or salts thereof. Particularly, the present invention relates to new pharmaceutical compositions for use in the treatment of pain and inflammatory symptoms associated with joint and cartilage disorders, especially with osteoarthritis and rheumatoid arthritis.
    Type: Application
    Filed: January 29, 2013
    Publication date: January 8, 2015
    Inventors: Umit Cifter, Ali Turkyilmaz, Onur Mutlu, Gaye Ramazanoglu